Rday
Sunday, March 15, 2026
19.9
C
Bengaluru
Hot topics
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
Customer Acquisition Cost (CAC) & Indian Pharma
Introduction
Customer Acquisition Cost (CAC) is a key metric representing...
Pharma Marketing in the New Age
Inside this Issue
1. Conference Notes: Pharma Marketing in the New...
Inspirational Frontline Leadership
The last issue of 2016, with articles from K. Hariram and Vivek Hattangadi and new authors, Dr. Ashwin Bonde and Diksha Fouzdar. Diksha's article is the highlight of this issue - an in-depth look at how to embed compliance in the very DNA of a pharma company.
Partner Don’t Punish
Articles by Vivek Hattangadi, Genesh Kuriakose, Pankaj Mehrotra, Salil Kallianpur and Jay Mehta
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
Hot topics
Role of AI Across Pharma Industry
Introduction
Artificial intelligence (AI) is increasingly pivotal in driving innovation...
Incentives in Healthcare: The Quiet Force Shaping Outcomes
In 2017, economist Richard Thaler won the Nobel Prize...
Customer Acquisition Cost (CAC) & Indian Pharma
Introduction
Customer Acquisition Cost (CAC) is a key metric representing...
Biocon Bats for Affordable Insulin and Ozempic
🩺 Insulin, Innovation, and Independence: How Biocon, Civica, and...
Navigating India’s Diverging Health Landscape and Field Force Optimisation
India’s health map is splitting into two distinct opportunity...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
Newsletter
Get important news delivered directly to your inbox and stay connected!